Mean weight loss of 19.2%I at 6 mg with no plateau and favorable safety profile in 48-week Phase 3 clinical trial – – Data ...

Zocilurtatug pelitecan shows promising results as a DLL3-targeted therapy for small cell lung cancer, with high response rates and ongoing trials.

PepGen shifts focus to PGN-EDODM1 for Myotonic Dystrophy Type 1 after discontinuing PGN-EDO51 for Duchenne Muscular Dystrophy ...

Gilead Sciences' HIV therapies and liver drug Livdelzi drive Q3 revenue growth, offsetting weaker Veklury and Cell Therapy ...

From lab bench to clinic, discover how a centuries-old superfruit translates into measurable gains in glycemic control, lipid profiles, skin health, and resilience against oxidative stress.

Recent Investor Day highlighted how AXPAXLI™ is positioned to redefine retina based on potential superiority label, market expansion, and immediate adoptability ...

First clinical data disclosure for CB-011 highlights its potential as a best-in-class allogeneic CAR-T cell therapy for relapsed or refractory ...

Against Leão, the focus is on forward Kaio Jorge, the top scorer of the Brazilian Championship alongside Uruguayan De Arrascaeta from Flamengo, with 15 goals. Kaio Jorge is the standout player for the ...

Detailed price information for Magna International Inc (MG-T) from The Globe and Mail including charting and trades.

The Cubi NUC AI 2MG is MSI's take on Intel’s Next Unit of Computing (NUC) mini PC concept, which enables system vendors to ...

Compelling results set new clinical standard in generalized myasthenia gravis (gMG), increasing confidence in the Company's registrational KYSA-6 Phase 3 MG trial 100% of patients achieved clinically ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces clinical data for CT0596, an allogeneic BCMA-targeting CAR-T ...